- Home
- CNTX vs QNCX Comparison
CNTX vs QNCX Comparison
Compare CNTX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- QNCX
- Stock Information
- Founded
- CNTX 2015
- QNCX 2012
- Country
- CNTX United States
- QNCX United States
- Employees
- CNTX N/A
- QNCX N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTX Health Care
- QNCX Health Care
- Exchange
- CNTX Nasdaq
- QNCX Nasdaq
- Market Cap
- CNTX 67.7M
- QNCX 62.0M
- IPO Year
- CNTX 2021
- QNCX 2019
- Fundamental
- Price
- CNTX $0.81
- QNCX $1.40
- Analyst Decision
- CNTX Strong Buy
- QNCX Strong Buy
- Analyst Count
- CNTX 5
- QNCX 4
- Target Price
- CNTX $6.70
- QNCX $9.50
- AVG Volume (30 Days)
- CNTX 147.9K
- QNCX 109.9K
- Earning Date
- CNTX 03-20-2025
- QNCX 03-31-2025
- Dividend Yield
- CNTX N/A
- QNCX N/A
- EPS Growth
- CNTX N/A
- QNCX N/A
- EPS
- CNTX N/A
- QNCX N/A
- Revenue
- CNTX N/A
- QNCX N/A
- Revenue This Year
- CNTX N/A
- QNCX N/A
- Revenue Next Year
- CNTX N/A
- QNCX N/A
- P/E Ratio
- CNTX N/A
- QNCX N/A
- Revenue Growth
- CNTX N/A
- QNCX N/A
- 52 Week Low
- CNTX $0.77
- QNCX $0.51
- 52 Week High
- CNTX $2.75
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CNTX 39.82
- QNCX 37.98
- Support Level
- CNTX $0.77
- QNCX $1.38
- Resistance Level
- CNTX $0.87
- QNCX $1.54
- Average True Range (ATR)
- CNTX 0.08
- QNCX 0.11
- MACD
- CNTX 0.01
- QNCX -0.00
- Stochastic Oscillator
- CNTX 20.75
- QNCX 9.37
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.